Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

被引：63

作者：

Skinner, MA ^{[1
]}

Laidlaw, SM ^{[1
]}

Eldaghayes, I ^{[1
]}

Kaiser, P ^{[1
]}

Cottingham, MG ^{[1
]}

机构：

[1] Inst Anim Hlth, Newbury RG20 7NN, Berks, England

来源：

EXPERT REVIEW OF VACCINES | 2005年 / 4卷 / 01期

基金：

英国生物技术与生命科学研究理事会;

关键词：

avian influenza virus; avipoxviruses; DNA prime-boost vaccination; infectious bursal disease virus; interleukin-18; live attenuated vaccine virus; Newcastle disease virus; nonreplicating poxvirus vectors;

D O I：

10.1586/14760584.4.1.63

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Live vaccines against fowlpox virus, which causes moderate pathology In poultry and is the type species of the Avipoxvirus genus, were developed in the 1920s. Development of recombinant fowlpox virus vector vaccines began in the 1980s, for use not only in poultry, but also In mammals including humans. In common with other avipoxviruses, such as canarypox virus, fowlpox virus enters mammalian cells and expresses proteins, but replicates abortively. The use of fowlpox virus as a safe vehicle for expression of foreign antigens and host immunomodulators, Is being evaluated in numerous clinical trials of vaccines against cancer, malaria, tuberculosis and AIDS, notably in heterologous prime-boost regimens. In this article, technical approaches to, and issues surrounding, the use of fowlpox virus as a recombinant vaccine vector In poultry and mammals are reviewed.

引用

页码：63 / 76

页数：14

共 118 条

[41]

Grosenbach DW, 2001, CANCER RES, V61, P4497

[42] Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice [J].